Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

Current Medical Research and Opinion

Volumn 28, Issue 7, 2012, Pages 1119-1127

  Henk, Henry ^a   Teitelbaum, April ^a   Kaura, Satyin ^b  

^a OPTUM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone; Cancer; Persistency; Retrospective claims analysis; Skeletal complications; Zoledronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CANCER; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CONTROLLED STUDY; EVALUATION; FEMALE; FRACTURE; HUMAN; KIDNEY CARCINOMA; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SPINAL CORD COMPRESSION; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; NEOPLASMS; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION;

EID: 84863610553     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.689254     Document Type: Article

References (30)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-9s (Pubitemid 44703797)
2. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84 (Pubitemid 40613323)
3. Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2:234-40
4. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with different types of cancer. Acta Oncol 2009;48:105-15
5. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7 (Pubitemid 47557312)
6. Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007;57:229-32 (Pubitemid 47044952)
7. Langford DJ, Tripathy D, Paul SM, et al. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain 2011;12:495-507
8. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32
9. Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol Ther 2006;5:1074-7 (Pubitemid 44772213)
10. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44 (Pubitemid 37238631)
11. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21 (Pubitemid 38715767)
12. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004;96:879-82 (Pubitemid 38807610)
13. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57 (Pubitemid 46606220)
14. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17
15. Zometa (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011
16. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009;7(Suppl 3):S1-32; quiz S3-5
17. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7
18. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
19. Hatoum HT, Lin SJ, Guo A, et al. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011;27:55-62
20. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
21. Body J-J, Cook R, Costa L, et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. In: Proceedings of the IX International Meeting on Cancer Induced Bone Disease; 2009 Oct 28-31. Poster 71
22. Costa L, Cook R, Body J-J, et al. Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. In: Proceedings of the IX International Meeting on Cancer Induced Bone Disease; 2009 Oct 28-31. Poster 50
23. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99
24. Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 2006;70:147-53 (Pubitemid 43760341)
25. Journe F, Magne N, Chaboteaux C, et al. Sequence-and concentrationdependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis 2006;23:135-47 (Pubitemid 44440173)
26. Ottewell PD, Lefley DV, Cross SS, et al. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522-32
27. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105
28. Spence MM, Hui RL, Chan J, et al. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. Ann Pharmacother 2010;44:1384-8
29. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87 (Pubitemid 33759002)
30. Shah SR, Jean GW, Keisner SV, et al. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer 2012;20:87-93